Reuters: Regulatory News: FDA staff question Novartis cystic fibrosis drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA staff question Novartis cystic fibrosis drug Aug 31st 2012, 12:38 WASHINGTON | Fri Aug 31, 2012 8:38am EDT WASHINGTON Aug 31 (Reuters) - U.S. drug reviewers questioned whether Novartis AG's inhaled antibiotic treatment truly helped cystic fibrosis patients breathe better, according to documents posted online on Friday. Staff from the U.S. Food and Drug Administration released their review of Novartis's tobramycin inhaled powder ahead of an advisory committee of outside experts, which will vote on whether to recommend the drug next Wednesday. Novartis is seeking approval of the inhaled antibiotic powder as a more convenient alternative than nebulized solution. The antibiotic attacks an infection that often occurs in the lungs of patients with cystic fibrosis, a rare genetic disease.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions